Healthcare & Life Sciences
ETCHX
- 1-Year
- 12.41%
- 5-Year
- 0.19%
- 10-Year
- 8.95%
- Since Inception
- 12.94%
Unless otherwise noted, all data is as of 09/30/2025. Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Morningstar ratings are based on risk-adjusted returns.
Fund Objective
Seeks to provide long-term capital appreciation.
About the Fund
A diversified mutual fund seeking long-term capital appreciation in the healthcare and life sciences sectors (≥80%). Concentrates investments in the drug-related industries (≥25%). May invest in illiquid securities (≤15%).
Fund Distinctives
Focused on Early Development-Stage Companies
Median market capitalization of $2.4 billion as of 09/30/2025.
Creating Compelling Value for Patients and Society
Targeting large unmet medical needs, rare and orphan diseases.
Access to Unique Offerings
Investing in IPOs, mezzanine financing offerings, and up to 15% in private investments.
At a Glance
- Benchmarks
- S&P Biotechnology Select Industry Index 3
- Morningstar Classification
- US Fund Health
-
Total Assets (as of
12/04/2025)
- $1.71 billion
- Inception Date
- 12/27/2012
- Number of Holdings
- 71
- Average Market Cap
- $9.3 billion
- Median Market Cap
- $2.4 billion
- Distribution Frequency
- Annually
Performance and Risk
Trailing Returns (%) As of the quarter ending 09/30/2025
| Eventide Healthcare & Life Sciences Fund | As of 12/04/2025 YTD | |||||||
|---|---|---|---|---|---|---|---|---|
| Class I | 58.54% | 21.61 | 13.54 | 10.32 | 1.20 | 10.04 | 14.08 | 12/27/2012 |
| Class A without load | 58.14% | 21.50 | 13.25 | 10.04 | 0.95 | 9.76 | 13.79 | 12/27/2012 |
| Class A with 5.75% load | 49.06% | 14.51 | 6.72 | 7.89 | -0.24 | 9.11 | 13.26 | 12/27/2012 |
| Class C | 57.05% | 21.28 | 12.41 | 9.21 | 0.19 | 8.95 | 12.94 | 12/27/2012 |
| Class N | 58.23% | 21.50 | 13.28 | 10.09 | 0.99 | 9.82 | 13.86 | 12/27/2012 |
| Benchmark | ||||||||
| S&P Biotechnology Select Industry Index3 | 36.91% | 20.91 | 1.53 | 8.34 | -1.88 | 5.08 | 10.35 | 12/27/2012 |
Calendar Year Returns (%)
| Eventide Healthcare & Life Sciences Fund, Class I | 15.17 | -16.03 | 45.83 | -0.15 | 58.74 | 37.04 | -16.60 | -19.62 | 11.01 | -10.13 | |
| S&P Biotechnology Select Industry Index3 | 13.09 | -15.61 | 43.85 | -14.99 | 32.34 | 48.10 | -20.38 | -25.62 | 7.76 | 1.18 | |
|
Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. This material must be read along with the Fund's prospectus, which may be obtained at eventidefunds.com/prospectus. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836). The returns shown do not reflect the deduction in taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes. Performance figures greater than 1 year are annualized. |
|||||||||||
Morningstar Ratings 2
Morningstar ratings are based on risk-adjusted returns. Morningstar rankings are based on total returns.
- Overall
-
- 165 Funds in Category
- 3 Year
-
3
- 24% Percentile of 165 Funds
- 5 Year
-
2
- 80% Percentile of 152 Funds
- 10 Year
-
2
- 19% Percentile of 118 Funds
Market Risk 10
Portfolio 15
Top 10 Holdings
| Holding | Weight (39.39%) |
|---|---|
| Insmed Inc Therapies for pulmonary infections and other lung diseases | 6.18% |
| Mirum Pharmaceuticals Inc Treating rare pediatric cholestasis diseases with IBAT inhibitors | 5.88% |
| Guardant Health Inc Cell diagnostics for cancer patients | 4.48% |
| Celcuity Inc Develops novel drugs for breast and prostate cancer | 4.00% |
| Scholar Rock Novel therapeutics for neuromuscular disorders and obesity | 3.67% |
| Axsome Therapeutics Inc Develops novel therapies for neurological and psychiatric diseases | 3.50% |
| Alnylam Pharmaceuticals Inc A pioneer in translating RNA Interference for medical applications | 3.42% |
| iRhythm Technologies Inc Provider of wearable patch-based monitor to detect cardiac arrhythmia | 2.85% |
| Kymera Therapeutics Inc Develops novel modalities for autoimmune and oncology | 2.71% |
| Argenx Biotechnology company that develops therapies for autoimmune diseases | 2.70% |
Portfolio Managers
Finny Kuruvilla, MD, PhD
Co-Chief Investment Officer, Senior Portfolio Manager, Managing Director, Founding Member
Finny Kuruvilla, MD, PhD, serves as Co-Chief Investment Officer and Senior Portfolio Manager for Eventide. He serves as the Lead Portfolio Manager for Eventide’s Strategic Growth, Healthcare & Life Sciences, and Technology Strategies. He also is a Managing Director for Eventide Ventures, as well as a Founding Member of Eventide.
Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital.
Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.
I-hung Shih, PhD
Portfolio Manager, Managing Director
I-hung Shih, PhD, serves as Co-Portfolio Manager for Eventide’s Healthcare Strategy, as well as a Managing Director for Eventide Ventures.
Prior to joining Eventide, Dr. Shih was Co-Head of the Biotech Private Investments team at Wellington Management. She also served as Global Industry Analyst and Co-Manager for Wellington’s Small-cap and SMID Cap Biotech Strategies. Before her tenure at Wellington Management, Dr. Shih was a Senior Biotech Analyst at T. Rowe Price, covering US biotech companies and Co-Managing the Institutional US Structured Research Fund. She also served as the Lead Officer for US biopharma investment in public and private equity at Temasek International and as an Associate in investment banking on the Credit Suisse Biotech Team.
Dr. Shih holds an MBA from the Wharton School, University of Pennsylvania, a PhD in Biochemistry from Duke University, and a BS in Chemistry from National Taiwan University. Additionally, she was a research fellow at the Whitehead Institute at MIT and the National Institutes of Health.
Literature
PDF, opens in a new windowImpact the world for good
Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.
This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at https://www.eventidefunds.com/prospectus or by calling 1-877-771-EVEN (3836). Investors should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.
- Returns are for Class C as of 09/30/2025 with an inception date of 12/27/2012. Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted.
- Past performance is no guarantee of future results.
The Morningstar Rating™ for funds, or ‘star rating’, is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product’s monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The Morningstar Rating does not include any adjustment for sales loads. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10- year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Ratings are determined monthly and subject to change.
% Rank in Category is the fund’s percentile rank for the specified time period relative to all funds that have the same Morningstar category. The highest (or most favorable) percentile rank is 1 and the lowest (or least favorable) percentile rank is 100. The top-performing fund in a category will always receive a rank of 1. Percentile ranks within categories are most useful in those categories that have a large number of funds.© 2025 Morningstar. All Rights Reserved. Morningstar is an independent provider of financial information. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
- The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. Source: Bloomberg Index Services Limited. Bloomberg® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively "Bloomberg"). Bloomberg or Bloomberg's licensors own all proprietary rights in the Bloomberg Indices. Neither Bloomberg nor Bloomberg's licensors approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index.
- For the Fund's fiscal year ending 06/30/2025.
Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year. A higher portfolio turnover may indicate higher transaction costs for the Fund and may result in higher taxes for investors.
- The range shows the highest and lowest turnover ratio reported in the Annual Report during the last three fiscal years ending 06/30/2025.
Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year. A higher portfolio turnover may indicate higher transaction costs for the Fund and may result in higher taxes for investors.
- Class A and Class C are also subject to a maximum deferred sales charge of 1.00%. This and other expenses that apply to a continued investment in the Fund are described in the Fund's prospectus.
- Refer to the Fund's SAI for definition of Other Expenses.
- Effective 06/01/2022, Class I shares purchased directly from the Funds are not subject to the minimum initial or subsequent investment requirements.
- Fund information is as of 09/30/2025. Benchmark is S&P Biotechnology Select Industry Index, and benchmark information is as of 09/30/2025. Source: Bloomberg. Active Share is the percentage of fund holdings that is different from the benchmark holdings. A higher percentage indicates a greater difference from the benchmark.
- Source: © Morningstar, Inc. (2025). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. The performance and risk factor comparisons are against the S&P Biotechnology Select Industry Index.
Annualized since inception figures use an inception date of 01/01/2013 and not the actual inception date of 12/27/2012 as only full month data is used in Market Risk calculations. - Standard Deviation of return measures the amount of variation in historical performance from period to period.
- Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index.
- Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of a fund relative to the return of the Index is a fund’s alpha.
- R-Squared is a measure of how a fund’s performance correlates with the Index’s performance and it can help assess how likely it is that beta is statistically significant.
- Allocation percentages and holdings are subject to change at any time, are subject to risks discussed in the Funds prospectus, and should not be considered investment advice.
Assets labeled Cash/Other may include cash, cash equivalents, money market funds, and options. Impact bonds, if invested, fund business models that strive to have significant social or environmental effects.
Due to rounding, numbers may not add up to 100.
Top Holdings are based on percentage of net assets and do not include cash/money market funds/equivalents.
Portfolio Composition Source: © Morningstar, Inc. (2025). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. - This chart is for illustrative purposes and assumes that a $10,000 investment was made on the Fund’s inception date of 12/27/2012 and that all dividends and capital gains were reinvested. Hypothetical performance often shows markedly better results than actual management and should not be the basis for an investment decision. A variety of factors could impact investment decision making or otherwise cause differences between the hypothetical performance and actual investor returns. Compares the Eventide Healthcare & Life Sciences Fund Class I’s performance to index performance over the periods shown. Performance will differ for other fund classes, based upon fees and commissions.
The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).
Eventide 1772-2390 - 12/05/2025 09:11am